Pharmacogenetics in diverse ethnic populations--implications for drug discovery and development.
It is widely acknowledged that the vast quantities of data now publicly available as a result of the human genome initiative have the potential to revolutionize the pharmaceutical industry. More tangibly to the drug development business, the dawn of the pharmacogenetics era has the potential to impact not only the discovery of new medicines but also the safety and efficacy of pharmaceutical agents. Coincident with these scientific advances is the emergence of new markets for pharmaceutical agents. Japan, which represents the world's second biggest market, is a good example. With the ICH E5 agreement in 1998 and a rapid change in the drug registration process in Japan, there are increasing opportunities to improve access to more medicines in all parts of the world. However, it is increasingly clear that significant genetic variation still exists between populations, with a host of data on interethnic variation in drug metabolizing enzyme and drug transporter activity. Evidence suggesting that this genetic variation may play an important role in defining some of the interethnic variation in drug response to currently marketed compounds is reviewed here, and future possibilities of using such information to better streamline the drug development process are discussed.
McCarthy
Linda C
LC
Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts, SG1 2NY, UK.
Davies
Kirstie J
KJ
Campbell
David A
DA
D015195:Drug Design; D004341:Drug Evaluation; D018432:Drug Resistance, Multiple / Q000235:genetics; D005006:Ethnicity / Q000235:genetics*; D006801:Humans; D004364:Pharmaceutical Preparations / Q000378:metabolism; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic
D004364:Pharmaceutical Preparations